Beneficial Effect of Upadacitinib in an Adult Patient with Juvenile Idiopathic Arthritis-associated Uveitis after Unsatisfactory Response to Tofacitinib: A Case Report.
Ocul Immunol Inflamm
; 31(5): 1079-1080, 2023 Jul.
Article
em En
| MEDLINE
| ID: mdl-35587645
ABSTRACT
OBJECTIVE:
Several case reports have been published on the effect of janus kinase inhibitors (JAK-I) on juvenile idiopathic arthritis-associated uveitis (JIAU). Both tofacitinib and baricitinib have been described as therapeutically effective in JIAU.METHODS:
We here present a case of a 24-years-old female with refractory course of JIAU receiving upadacitinib therapy.RESULTS:
After failing multiple conventional and biologic disease-modifying antirheumatic drugs, the patient finally achieved clinical remission on upadacitinib monotherapy, despite a previously unsatisfactory clinical response of both arthritis and uveitis to tofacitinib monotherapy.CONCLUSION:
This case suggests that switching JAK-I might be a successful strategy in the treatment of JIAU, despite previously incomplete response to other preparations.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Juvenil
/
Uveíte
/
Antirreumáticos
/
Inibidores de Janus Quinases
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article